The inhaled GLP-1 products will be developed in Iconovo’s proprietary inhalers, primarily as a treatment for obesity with the opportunity to include other metabolic diseases like type 2 diabetes, fatty liver disease, cardiovascular disease and sleep apnea. The investments required in the initial development phase are limited.
“As a leading inhalation company, with a range of fully developed inhaler platforms and the competence to formulate pharmaceutical compounds into powders, we are in a perfect position to take a step into reformulation of selected high-value products in areas where inhalation can offer significant patient benefits. We are very excited to take this important step towards the development of a next generation of patient-friendly GLP-1 treatments with sustained efficacy”, says Johan Wäborg, CEO of
Most of today’s GLP-1 treatments, like Zepbound® (Eli Lilly) and Wegovy® (
At present there is one oral GLP-1 treatment on the market, and more are under development. So far, bioavailability has been a major challenge with only about 1% of the active drug reaching its target.
The patent application for inhaled GLP-1 receptor agonists addresses a very large and rapidly growing market presently worth
© Modular Finance, source